Pirarubicin (THP) is an important chemotherapy agent of TACE that is usually used in HCC combination therapy.6, 35 Interestingly, we found that THP, as an inhibitor for MARCH1, could accelerate cell apoptosis and decrease the proliferation, migration and invasion in HCC cells also via the PI3K‐AKT‐β‐catenin signalling pathway. This evidence concerns the gene MARCHF1 and hepatocellular carcinoma.